FDA approves first-in-class cancer metabolism drug,Nature Reviews Drug Discovery

当前位置： X-MOL 学术 › Nat. Rev. Drug. Disc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

FDA approves first-in-class cancer metabolism drug
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-09-01 , DOI: 10.1038/nrd.2017.174
Asher Mullard

The FDA approved Agios' and Celgene's enasidenib for acute myeloid leukaemia (AML), validating metabolism-modulating drugs as a means of killing cancer cells.Enasidenib (formerly AG-221) is a first-in-class inhibitor of mutated isocitrate dehydrogenase 2 (IDH2). The IDH enzymes normally metabolize isocitrate into α-ketoglutarate. When

中文翻译：

FDA批准了一流的癌症代谢药物

FDA批准了Agios和Celgene的enasidenib用于急性髓细胞性白血病（AML），验证了代谢调节药物可杀死癌细胞的方法.Enasidenib（前身为AG-221）是突变的异柠檬酸脱氢酶2（ IDH2）。IDH酶通常将异柠檬酸代谢成α-酮戊二酸。什么时候

更新日期：2017-09-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>